Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer

Pharmacogenomics

Volumn 9, Issue 5, 2008, Pages 539-549

  Obradovic, Marko ^a   Mrhar, Ales ^a   Kos, Mitja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Colorectal cancer; Cost effectiveness; Decision analysis; Irinotecan; UGT1A1 genotyping

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN;

ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAUCASIAN; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; GENETIC ANALYSIS; GENOTYPE; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEGRO; NEUTROPENIA; OUTCOME ASSESSMENT; PLESIOMORPHY; POPULATION RESEARCH; QUALITY ADJUSTED LIFE YEAR; SURVIVAL TIME;

CAMPTOTHECIN; COHORT STUDIES; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS;

EID: 44949103148     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.5.539     Document Type: Article

References (57)

1. Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49, 5077-5082 (1989).
2. Cunningham D, Pyrhonen S, James RD et al.: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352, 1413-1418 (1998).
3. Douillard JY, Cunningham D, Roth AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041-1047 (2000).
4. Rougier P, Lepille D, Bennouna J et al.: Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre Phase II study. Ann. Oncol. 13, 1558-1567 (2002).
5. Saltz LB, Cox JV, Blanke C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343, 905-914 (2000).
6. Tournigand C, Andre T, Achille E et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22, 229-237 (2004).
7. Carlini LE, Meropol NJ, Bever J et al.: UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin. Cancer Res. 11, 1226-1236 (2005).
8. Hahn KK, Wolff JJ, Kolesar JM: Pharmacogenetics and irinotecan therapy. Am. J. Health Syst. Pharm. 63, 2211-2217 (2006).
9. O'Dwyer PJ, Catalano RB: Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J. Clin. Oncol. 24, 4534-4538 (2006).
10. Crawford J, Dale DC, Lyman GH; Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100, 228-237 (2004).
11. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT: Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103, 1916-1924 (2005).
12. Lyman GH, Kuderer NM: The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit. Rev. Oncol. Hematol. 50, 129-146 (2004).
13. Mathijssen RH, Loos WJ, Verweij J, Sparreboom A: Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr. Cancer Drug Targets 2, 103-123 (2002).
14. Takimoto CH, Wright J, Arbuck SG: Clinical applications of the camptothecins. Biochim. Biophys. Acta 1400, 107-119 (1998).
15. Iyer L, King CD, Whitington PF et al.: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101, 847-854 (1998).
16. Haaz MC, Rivory L, Jantet S, Ratanasavanh D, Robert J: Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol. Toxicol. 80, 91-96 (1997).
17. Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA 95, 8170-8174 (1998).
18. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, di Rienzo A: Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 9, 591-599 (1999).
19. Fertrin KY, Goncalves MS, Saad ST, Costa FF: Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am. J. Med. Genet. 108, 117-119 (2002).
20. Lampe JW, Bigler J, Horner NK, Potter JD: UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 9, 341-349 (1999).
21. Liu JY, Qu K, Sferruzza AD, Bender RA: Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals. Anticancer Drugs 18, 693-696 (2007).
22. Iyer L, Das S, Janisch L et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2, 43-47 (2002).
23. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926 (2000).
24. Han JY, Lim HS, Shin ES et al.: Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24, 2237-2244 (2006).
25. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004).
26. Marcuello E, Altes A, Menoyo A, del Rio E, Gomez-Pardo M, Baiget M: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91, 678-682 (2004).
27. Massacesi C, Terrazzino S, Marcucci F et al.: Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106, 1007-1016 (2006).
28. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10, 5151-5159 (2004).
29. Toffoli G, Cecchin E, Corona G et al.: The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 24, 3061-3068 (2006).
30. Rougier P, Lepere C: Second-line treatment of patients with metastatic colorectal cancer. Semin. Oncol. 32, S48-S54 (2005).
31. Hasegawa Y, Sarashina T, Ando M et al.: Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin. Chem. 50, 1479-1480 (2004).
32. Aapro MS, Cameron DA, Pettengell R et al.: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur. J. Cancer 42, 2433-2453 (2006).
33. Arriagada R, le Chevalier T, Pignon JP et al.: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N. Engl. J. Med. 329, 1848-1852 (1993).
34. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N. Engl. J. Med. 332, 901-906 (1995).
35. Kaye SB, Paul J, Cassidy J et al.: Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J. Clin. Oncol. 14, 2113-2119 (1996).
36. Samson MK, Rivkin SE, Jones SE et al.: Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer 53, 1029-1035 (1984).
37. Wood WC, Budman DR, Korzun AH et al.: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N. Engl. J. Med. 330, 1253-1259 (1994).
38. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B: Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7, 518-528 (2004).
39. Zhang A, Xing Q, Qin S et al.: Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations. Pharmacogenomics J. 7, 333-338 (2007).
40. Earle CC, Kwok A, Gazelle GS, Fuchs CS: Two schedules of second-line irinotecan for metastatic colon carcinoma. Cancer 101, 2533-2539 (2004).
41. Lyman GH, Kuderer NM, Djulbegovic B: Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am. J. Med. 112, 406-411 (2002).
42. McLeod HL, Parodi L, Sargent DJ et al.: UGT1A1*, toxicity and outcome in advanced colorectal cancer: results from Trial N9741. J. Clin. Oncol. 24(S18) (2006) (Abstract 3520).
43. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst. 99, 1290-1295 (2007).
44. Rougier P, Lepere C: Metastatic colorectal cancer: first- and second-line treatment in 2005. Semin. Oncol. 32, 15-20 (2005).
45. Norum J: Cetuximab in the treatment of metastatic colorectal cancer: a model-based' cost-effectiveness analysis: J. Chemother. 18, 532-537 (2006).
46. Starling N, Tilden D, White J, Cunningham D: Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br. J. Cancer 96, 206-212 (2007).
47. Tappenden P, Jones R, Paisley S, Carroll C: Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol. Assess. 11, 1-128 (2007).
48. Shiroiwa T, Fukuda T, Tsutani K: Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin. Ther. 29, 2256-2267 (2007).
49. Ychou M, Raoul IL, Desseigne F et al.: High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer Chemother. Pharmacol. 50, 383-391 (2002).
50. Ducreux M, Ychou M, Seitz JF et al.: Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding anq pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J. Clin. Oncol. 17, 2901-2908 (1999).
51. Undevia SD, Gomez-Abuin G, Ratain MJ: Pharmacokinetic variability of anticancer agents. Nat. Rev. Cancer 5, 447-458 (2005).
52. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B: Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347, 578-581 (1996).
53. Goldberg RM, Sargent DJ, Morton RF et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22, 23-30 (2004).
54. Calhoun EA, Chang CH, Welshman EE, Fishman DA, Lurain JR, Bennett CL: Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 6, 441-445 (2001).
55. Cosler LE, Calhoun EA, Agboola O. Lyman GH: Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 24, 488-494 (2004).
56. Lyman GH: A predictive model for neutropenia associated with cancer chemotherapy. Pharmacotherapy 20, S104-S111 (2000).
57. Lyman GH, Lyman CG, Sanderson RA, Balducci L: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J. Natl Cancer Inst. 85, 488-493 (1993).